Lenalidomida Teva

Lenalidomide, the active ingredient in Lenalidomida Teva, is a Immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with the del(5q) chromosome abnormality.

GNH USA supplies Lenalidomida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomida Teva is an immunomodulatory agent used in specific hematologic malignancies.

Multiple myeloma: improves disease control and prolongs survival in patients with relapsed or refractory disease. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can lead to cytogenetic remission.

Lenalidomida Teva may cause a range of adverse reactions.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels causing bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin irritation or erythema. - Nausea: feeling of sickness often accompanied by vomiting.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury. - Embryo‑fetal toxicity: severe birth defects if exposure occurs during pregnancy.

Before initiating therapy, clinicians should evaluate patient risk factors and monitor laboratory parameters.

Pregnancy contraindication: avoid use in pregnant women; teratogenic risk is category X. Thromboembolic risk: assess need for prophylactic anticoagulation. Renal impairment: adjust monitoring for patients with reduced kidney function. Hematologic monitoring: regular CBC to detect neutropenia or thrombocytopenia. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lenalidomida Teva can interact with several concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - P-glycoprotein inhibitors: may elevate plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure. - Immunosuppressants (e.g., cyclosporine): potential additive hematologic toxicity. - Vaccines: live attenuated vaccines should be avoided during treatment.